Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Hifas Intima Oral on Vaginal Microbiota in Healthy Women
Sponsor: Hifas da Terra S.L.
Summary
The goal of this clinical trial was to learn whether the vaginal microbiota changed after healthy women aged 18 to 45 years took Hifas Intima, an oral food supplement, for 3 months. The study also evaluated changes in vaginal pH and vaginal health and collected information about adverse events, tolerability, adherence, and participant satisfaction. The main questions it aimed to answer were: Did the composition of the vaginal microbiota change after participants took Hifas Intima for 3 months? Did vaginal pH or vaginal health change during the study? What medical problems or tolerability issues did participants have while taking Hifas Intima? How closely did participants follow the supplementation schedule, and how satisfied were they with the supplement? All participants received Hifas Intima. The study did not include a placebo or another comparison group. Participants were asked to: Take one capsule of Hifas Intima by mouth once daily for 12 weeks Attend one study visit before starting supplementation and another visit after 3 months Provide vaginal samples at both visits to assess the vaginal microbiota Undergo gynecological assessments, including measurement of vaginal pH and vaginal health Have a urine pregnancy test at both visits Report medical problems and provide information about tolerability, adherence, and satisfaction with the supplement
Official title: Open-label Clinical Trial to Evaluate the Effect of the Hifas Intima Food Supplement on the Vaginal Microbiota of Healthy Women
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-06-11
Completion Date
2026-03-17
Last Updated
2026-07-20
Healthy Volunteers
Yes
Interventions
Hifas INTIMA Oral
Participants took one capsule of Hifas Intima orally once daily, on an empty stomach before a main meal, for 12 weeks. Each capsule contained Ganoderma lucidum fruiting body powder 200 mg; Salvia lavandulifolia leaf and stem dry extract 53.33 mg, providing 8 mg of ursolic acid; D-mannose; inulin 45 mg; Lactobacillus acidophilus La-14® 8 × 10\^9 colony-forming units; vitamin C 12 mg; Lactobacillus crispatus 1 × 10\^9 colony-forming units; Lactobacillus gasseri 1 × 10\^9 colony-forming units; Lacticaseibacillus rhamnosus HN001™ 2 × 10\^9 colony-forming units; and vitamin A 121 micrograms.
Locations (1)
Instituto Palacios, Salud y Medicina de la Mujer
Madrid, Madrid, Spain